Research reveals that targeting TRPV6 and CXCR4 significantly reduces metastasis in castration-resistant prostate cancer, highlighting a promising combined therapy approach.
Key Points
Targeting trpv6 and cxcr4 complexes prevents bone metastasis in castration-resistant prostate cancer.
In mice, trpv6+/+ tumors showed increased metastasis, while trpv6-/- tumors showed no metastasis.
Using a monoclonal antibody against TRPV6 led to significant reduction in metastatic burden and increased survival rates.
Combination therapy with AMD3100 and TRPV6 targeting demonstrated a synergistic effect on metastasis suppression.